News and Insights
ChemT Biotechnology Joins Cell Manufacturing Research Initiative to Advance Scalable Biomanufacturing
ChemT Biotechnology has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT). CMaT is a consortium of universities, companies, and clinical collaborators brought together to develop transformative tools and technologies for the consistent, scalable and low-cost production of high-quality living therapeutic cells.
Know More
ChemT Biotechnology and CARsgen Therapeutics Announce Strategic Partnership to Advance Cell Therapy Innovation
Singapore, Dec 2025 — ChemT Biotechnology and CARsgen Therapeutics have entered into a strategic partnership focused on accelerating next-generation cell therapy development and exploring potential IND-enabling collaboration opportunities.
Know More
ChemT Marks a Milestone Moment on the NASDAQ Times Square Tower
New York, Nov 2025 — ChemT Biotechnology was featured on the NASDAQ Times Square tower in New York, marking the conclusion of its participation in the BioTools Innovator 2025 cohort. The milestone reflects a year of rapid progress in advancing its AI-powered biotechnology platform.
ChemT Biotech joins as a member of Lilly TuneLab™
ChemT Biotech is proud to become a member of Lilly TuneLab™, Eli Lilly’s AI/ML-enabled innovation platform designed to support companies with access to advanced predictive models for drug discovery and development. This partnership aligns closely with ChemT’s mission to build CelMo™, our AI-driven “Virtual Cell” platform that understands and predicts cell behavior, with downstream capabilities including AI agents...
ChemT Biotechnology Co-Founders to Speak at ISPE Singapore Conference 2025
Singapore, August 2025 – ChemT Biotechnology Co-Founders Dr. Ling Wu and Ms. Jie Sun will speak at the ISPE (International Society for Pharmaceutical Engineering) Singapore Conference 2025, held 27–29 August at Suntec Singapore.
Know More
ChemT Biotechnology Joins Ignition AI Accelerator
Singapore, August 2025 – ChemT Biotechnology has been selected for the Ignition AI Accelerator Program, an initiative backed by Tribe, NVIDIA, and Digital Industry Singapore (DISG) to advance high-impact AI innovations.
Know More
ChemT Biotechnology Unveils New Packaging for Flagship Product
Singapore, July 2025 – ChemT Biotechnology has introduced new packaging for its first commercial product, marking a milestone in the company’s journey from R&D to market delivery...
Know More
ChemT Biotechnology Becomes First Singapore Company Selected for BioTools Innovator 2025 Accelerator
Singapore, June 2025 – ChemT Biotechnology has been selected for the BioTools Innovator 2025 Accelerator Program, one of the world’s leading accelerators for the biotech sector. This year’s program saw over 420 applicants from around the globe, with only 30 companies chosen — making ChemT the first Singapore-based company in the program’s history.
Know More
ChemT Biotechnology Showcases Chemplify at ISCT 2025 in New Orleans
New Orleans, May 2025 – ChemT Biotechnology President and Cofounder Dr. Ling Wu participated in the International Society for Cell & Gene Therapy (ISCT) 2025 conference in New Orleans, engaging with global leaders in cell therapy and highlighting its proprietary AI-designed small molecule...
Know More
ChemT Biotechnology Presents AI Strategy to Address Biologics Bottlenecks at BILS 2025
Singapore, April 15, 2025 – ChemT Biotechnology took part in the Bio Innovation Leaders Summit (BILS) held in Singapore this week. Co-founder Dr. Ling Wu delivered a keynote address on leveraging artificial intelligence to enhance efficiency in biologics...
Know More
ChemT Co-Founders Discuss AI’s Role in Drug Discovery at April 2025 Panel
Singapore April 2025 – ChemT Biotechnology Co-Founders Ms. Jie Sun and Dr. Ling Wu joined industry leaders John Ng of Dark Horse Consulting, Sen (Sean) Lin of ChemLex, and Dr. Qiusong Tang of Roche in an April 2025 panel on the future of artificial intelligence...
Know More
ChemT Biotechnology Received a Letter of Support from Cytiva to Advance Cell Therapy Manufacturing
Singapore, December 20, 2024 – ChemT Biotechnology is working closely with Cytiva, a global leader in bioprocessing and cell therapy technologies, to support innovation and progress in cell therapy manufacturing. The collaboration focuses on integrating ChemT Bio’s flagship product, Chemplify™, into key stages...
ChemT Biotechnology Appoints Biomanufacturing Pioneer Prof. Charlie Cooney as Advisor
Singapore, December 15, 2024 – ChemT Biotechnology is delighted to welcome Prof. Charlie Cooney, Robert T. Haslam Professor Emeritus of Chemical Engineering at MIT, as an advisor to the company.
ChemT Biotechnology Becomes First Singapore Company Selected for BioTools Innovator 2025 Accelerator
Singapore, June 2025 – ChemT Biotechnology has been selected for the BioTools Innovator 2025 Accelerator Program, one of the world’s leading accelerators for the biotech sector. This year’s program saw over 420 applicants from around the globe, with only 30 companies chosen — making ChemT the first Singapore-based company in the program’s history.
Know More
ChemT Biotechnology Raises US$5 Million in 18 months to bring AI to Biomanufacturing
● The total funding comprises US$1 million in angel investment and a US$4 million seed round. The seed financing round was led by Wavemaker Ventures,with participation by SEEDS, further supported by notable investors across the United States and Asia.
Know More